Sentana-Lledo Daniel, Morgans Alicia K
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
Dana-Farber Cancer Institute, Boston, MA, USA.
Ther Adv Med Oncol. 2024 Dec 11;16:17588359241305088. doi: 10.1177/17588359241305088. eCollection 2024.
Patients with genitourinary (GU) malignancies have seen the development of multiple life-prolonging treatments in the past decade. As patients and clinicians consider their treatment options along the cancer journey, time spent with healthcare contact, or "time toxicity," has emerged as a new outcome measure that comprehensively considers time receiving cancer care, including planned visits for evaluation and treatment as well as unplanned urgent care addressing complications. Despite its rising study across cancer populations, there has been a surprising lack of work evaluating time toxicity in patients with GU cancers. This narrative review aims to summarize the available studies on time toxicity in cancer, with a deeper dive into the methodology, strengths and limitations, and future directions of the field. A dedicated section focused on scenarios and best practices to measure and collect data on time toxicity can serve to spark interest in evaluating this novel health outcome on GU cancer survivors. Ultimately, time toxicity is a relevant patient-centered metric that can be incorporated into clinical trial design and routine clinical care to influence clinical decision-making.
在过去十年中，泌尿生殖系统（GU）恶性肿瘤患者出现了多种延长生命的治疗方法。随着患者和临床医生在癌症治疗过程中考虑他们的治疗选择，与医疗接触所花费的时间，即“时间毒性”，已成为一种新的结果指标，它全面考虑了接受癌症治疗的时间，包括计划内的评估和治疗就诊以及处理并发症的非计划内紧急护理。尽管在癌症患者群体中对其研究日益增多，但令人惊讶的是，针对GU癌症患者的时间毒性评估工作却很少。本叙述性综述旨在总结癌症时间毒性的现有研究，深入探讨该领域的方法、优势和局限性以及未来方向。专门针对测量和收集时间毒性数据的场景及最佳实践的部分，有助于激发对评估GU癌症幸存者这一新型健康结果的兴趣。最终，时间毒性是一个以患者为中心的相关指标，可纳入临床试验设计和常规临床护理中以影响临床决策。
